Immune Checkpoint Inhibitors with Dr. Kerry Reynolds

On this episode of Curbside Consults, we discuss current approaches, adverse effects, and management of complications associated with immune checkpoint inhibitors (ICIs). We are joined by Dr. Kerry Reynolds, Clinical Director of Inpatient Oncology at Massachusetts General Hospital and Director of Severe Immunotherapy Complications Service.

Articles mentioned in this episode:

1. Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021.
2. Haanen J et al. Management of Toxicities from immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-up. Ann Oncol 2022.
3. Thompson JA et al. Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022.
4. Brahmer JA et al. Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events. J Immunother Cancer 2021.
5. Naidoo J et al. A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. J Clin Oncol 2018.

The Curbside Consults series complements the foundational information in Rotation Prep by taking a deep dive into key clinical topics with expert clinicians and educators. These podcasts explore and critique the evidence behind clinical practice and break down statistical concepts for the busy clinical trainee.

Kerry Reynolds, MD, is an Assistant Professor of Medicine at Harvard Medical School and Clinical Director of Inpatient Oncology and Director of Severe Immunotherapy Complications Service, Oncology, Massachusetts General Hospital.Mridula Nadamuni, MD, is a 2022–2023 NEJM Editorial Fellow. She completed her internal medicine/pediatrics residency and chief residency at UT Southwestern Medical Center.